Frazier Life Sciences Management L.P. Increases Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Frazier Life Sciences Management L.P. grew its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 140.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,165,591 shares of the biotechnology company’s stock after acquiring an additional 1,265,891 shares during the quarter. AnaptysBio comprises about 2.5% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 12th biggest position. Frazier Life Sciences Management L.P. owned approximately 7.93% of AnaptysBio worth $54,270,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. First Light Asset Management LLC increased its holdings in shares of AnaptysBio by 56.4% in the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock valued at $26,500,000 after acquiring an additional 446,372 shares during the period. Great Point Partners LLC boosted its position in shares of AnaptysBio by 9.2% in the 4th quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock worth $20,927,000 after purchasing an additional 82,648 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of AnaptysBio by 38.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 306,633 shares of the biotechnology company’s stock worth $7,684,000 after purchasing an additional 84,795 shares in the last quarter. StemPoint Capital LP boosted its position in shares of AnaptysBio by 499.0% in the 1st quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock worth $6,070,000 after purchasing an additional 224,548 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of AnaptysBio by 52.4% in the 2nd quarter. Renaissance Technologies LLC now owns 152,702 shares of the biotechnology company’s stock worth $3,827,000 after purchasing an additional 52,502 shares in the last quarter.

Insider Activity at AnaptysBio

In related news, Director Hollings Renton sold 10,000 shares of AnaptysBio stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $30.64, for a total value of $306,400.00. Following the completion of the transaction, the director now owns 1,950 shares in the company, valued at approximately $59,748. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. Following the completion of the sale, the insider now directly owns 11,618 shares in the company, valued at approximately $406,630. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Hollings Renton sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $30.64, for a total value of $306,400.00. Following the sale, the director now owns 1,950 shares of the company’s stock, valued at $59,748. The disclosure for this sale can be found here. Insiders sold a total of 33,940 shares of company stock worth $1,251,836 in the last 90 days. Corporate insiders own 33.70% of the company’s stock.

AnaptysBio Stock Down 2.0 %

Shares of ANAB stock opened at $31.87 on Friday. The stock has a market cap of $870.66 million, a PE ratio of -5.19 and a beta of -0.29. The business has a 50-day simple moving average of $35.68 and a 200-day simple moving average of $28.15. AnaptysBio, Inc. has a 52-week low of $13.36 and a 52-week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The business had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. Sell-side analysts anticipate that AnaptysBio, Inc. will post -6.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ANAB has been the subject of a number of recent analyst reports. Truist Financial raised their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Wedbush reaffirmed an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a research report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. lifted their price target on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.10.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.